Thanks for the views Finfree
Currently selling average 90,000 per month.
Assuming they keep that up for 12 months ( disregard the 50 new clients added, as not knowing how big they are, hard to say )
That's 10 Mil a year.
Add New Zealand into that and the 50 clients expected in the next quarter, it seems reasonable the amount of tests sold will be 11-15 Million in 2022.
Add the 'volume' that Mylan have ordered and UK ( Owen Mumford ) to be recorded in Q3, and the company is in pretty good shape.
Plus there is a fair chance TGA will give carestart approval. ( don't hold your breath )
Many countries, UK, US, have had failed, rejected, faulty RAT's to deal with except NZ and Australia. In that respect happy for AT1 to be a bit smaller, go steady.
